ALBERTA PRECISION LABORATORIES

Laboratory Bulletin

Leaders in Laboratory Medicine

DATE:	2022 May 18
TO:	All Clinicians at Connect Care Live Sites & All Community Providers/Prescribers, All Zones
FROM:	Dr Etienne Mahe, Hematopathologist & Medical Informatics Lead, South Sector, APL
RE:	Changes to Request Processes for Hemostasis Investigations, Hereditary Thrombophilia/Thrombosis Investigations & Antiphospholipid Syndrome/Lupus Investigations

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective Immediately, clinician providers/prescribers must follow new ordering processes for Hemostasis, Hereditary Thrombophilia/Thrombosis investigations and Antiphospholipid Syndrome/Lupus Investigations in Connect Care (including inpatients and Connect Care ambulatory patients). This applies to all sites that are live on Connect Care, but does not apply to sites still using legacy systems. For community practitioners, the laboratory has designed fillable PDF requisitions that mirror the ordering process in Connect Care (see web links below).
- These changes do not apply to routine coagulation testing such as PT/INR, aPTT, D-Dimer or anti-Xa testing. These changes also do not apply to routine antithrombin testing, orderable in Edmonton ONLY.

Background

- Hemostasis and hereditary thrombophilia/thrombosis investigations are high complexity and resource intensive laboratory testing workflows. Hemostasis investigations involve the stepwise testing of several analytes of significance to bleeding risk (e.g. clotting factors, von Willebrand factor (vWF), factor inhibitors, and other specialized tests); hereditary thrombophilia/thrombosis investigations involve the stepwise testing of analytes of significance to clotting risk (e.g. FV Leiden and prothrombin gene mutation analysis, protein C, S and antithrombin testing).
- To improve laboratory efficiency, and in line with the Choosing Wisely recommendations, hemostasis and hereditary thrombophilia/thrombosis investigations now require that providers/prescribers answer a series of cascading order questions. These questions will provide the laboratory with the necessary information to ensure that appropriate testing is performed, and will assist providers in determining if testing is indicated given the clinical context. These new processes also apply to any existing or future therapy plans and order sets.
- The cascading ordering process in Connect Care will prevent inappropriate ordering based on provider responses. Connect Care users MUST use the ordering processes in Connect Care (and NOT paper requisitions). Community providers using paper requisitions must FULLY and ACCURATELY complete the requisition(s), or testing may be cancelled.
- The laboratory investigation of Antiphospholipid Syndromes typically involves the testing of three important analytes, including lupus anticoagulant, and anti-cardiolipin and anti-beta-2-glycoprotein antibodies. Previous ordering in Connect Care required users to order these three analytes separately. Connect Care now provides prescribers/providers the ability to order all three in a single panel.



How this will impact you

- Connect Care Users: Hemostasis Investigations
- The following screenshot summarizes the cascading order questions required for requesting Hemostasis investigations. Note that there is a "default" selection of PTT and PT/INR; other tests can be added as appropriate.

Hemostasis Investigations Blood							
Submitter:	Edmonton Community Test 🔎 🗹 Bill Account:						
Is the patient currently on any anticoagulants?							
	None	Heparin (unfractionated or low-molecular) Vitamin K Antagonist (eg. warfarin)					
	Other ((eg. apixaban, rivaroxaban, fondaparinux, dabigatran, etc)					
Has the patient been o	diagnose	d with a bleeding disorder?					
	Yes	No					
Does the patient have	a family	history of bleeding or bleeding disorder?					
	Yes	No					
Does patient have a history of bleeding?	Yes	No					
Has patient received b	lood con	nponents or plasma derivatives?					
	Yes I	No					
Is the patient currently	y pregnar	nt or post-partum?					
	Yes I	No					
Is the patient on any e	estrogen (containing medication (including birth control)?					
	Yes I	No					
Coagulation Screening Tests:	🗸 Parti	ial Thromboplastin Time (PTT) / Prothrombin Time (PT/INR) Fibrinogen Thrombin Time					
von Willebrand Factor (VWF) Evaluation:	□ vwf	Screening Evaluation (Includes FVIII activity, VWF antigen, VWF function) UWF Antigen only					
Inhibitor Screens/Mixing Studies:	□ PTT	Inhibitor Screen/Mixing Study 🗌 PT Inhibitor Screen/Mixing Study 🗌 Lupus Anticoagulant					



PTT-Based Factor Assays:	Factor VIII Activity Factor IX Activity Factor XI Activity Factor XII Activity
PT-Based Factor Assays:	Factor II Activity Factor V Activity Factor VII Activity Factor X Activity
Specific Inhibitor Screen:	Factor VIII Inhibitor Factor IX Inhibitor Other
Hematologist Orderable Only:	Factor XIII Chromogenic Factor VIII Activity Chromogenic Factor IX Activity

Connect Care Users: Hereditary Thrombophilia/Thrombosis Investigations


The following screenshots summarize the cascading order questions required for requesting Hereditary Thrombophilia/Thrombosis Investigations.

Clinics/clinic members who routinely work with patients with Hereditary Thrombophilia/Thrombosis (or are at risk thereof) can indicate "Yes" to the first order question and will immediately be able to select the appropriate test(s).

Hereditary Thromboph	✓ Accept	ot X <u>C</u> ancel						
Are you a member of		~						
	Yes N							
Which tests are	🗸 Partia	I Thromboplastin Time (PTT) / Prothrombin Time (PT/INR) Factor V Lei	den					
required?	Prothrombin G20210A Variant Protein C Protein S Antithrombin							
	Antiphospholipid Syndrome Investigation (includes lupus anticoagulant, anti-cardiolipin antibody, and anti-beta-2-g							
	🗌 Not Ir	ndicated/Illegible						
Is the patient current	tly on any	anticoagulants?						
	None	Heparin (unfractionated or low-molecular) Vitamin K Antagonist (eg. wa	rfarin)					
	Other (e	g. apixaban, rivaroxaban, fondaparinux, dabigatran, etc)						
Is the patient current	Is the patient currently pregnant or post-partum?							
	Yes N	10						
Is the patient on any estrogen containing medication (including birth control)?								
	Yes N	10						
Thank you for			Q					
choosing wisely.								



Note that inappropriate order responses will result in the following message:



Connect Care Users: Antiphospholipid Syndrome/Lupus Investigation

This panel is orderable within the Hereditary Thrombophilia/Thrombosis Panel, **or as a stand-alone panel**. The stand-alone Antiphospholipid Syndrome/Lupus Investigation panel order screen is shown in the screenshot below. This stand-alone panel includes the following analytes: lupus anticoagulant, anti-cardiolipin antibody (IgG), and anti-B2GPI (IgG). NOTE: individual analytes (red arrows) can be "de-selected" as required.

Providers/prescribers are reminded of the need to indicate the reason(s) for testing, as well as all anticoagulant medications that the patient is currently taking.

Antiphospholipi	d Syndron	ne Inves	tigation Bl	bod						<mark>√ A</mark> ccep	t X <u>C</u> ancel
Process Inst.:	Order ALE	RT! Prio	to proceeding	, see link belo	w						~
Reference Links: Status:	1. DynaLlF Normal		-	2. AP T	est Directory						
	Expected	Date:	Ċ.	Today To	morrow 1 W	eek 2 Weeks	1 Month	3 Months	6 Months	Approx.	
	Expires:	0	6/05/2023 🗔								
Priority:	Routine	,O	Routine STA	Т							
Class:	Lab Colle	ct 🔎	Lab Collect	Clinic Collect	Third Party	•		•			
Specimen Type:	Blood	9	Blood								
Specimen Src:	Blood	9	Blood								
Submitter:			8								
Select tests to performed:	be	🖌 Lupu	s Anticoagulan	t 🗸 Anti-ca	rdiolipin Antib	ody 🗸 Anti-b	eta-2-glyco	protein I			
Reason for test (Select all that	-	Thron	mboembolism	Autoimn	nune Disorder	E Fertility Inv	estigation	Pregnancy	/ Loss 🗌 Pr	rolonged PTT [Other
Is the patient c		None	Heparin (unfra	actionated or	low-molecular)	Vitamin K A	ntagonist (e	g. warfarin)			
on any anticoagulants		Other (e	eg. apixaban, ri	varoxaban, fo	ndaparinux, da	bigatran, etc)					

Community Providers/Prescribers (not on Connect Care)

- Community Providers/Prescribers requesting hemostasis or hereditary thrombophilia/thrombosis investigations must use the new paper requisitions available through the Alberta Precision Laboratories website:
- Special Coagulation Testing Requisition Thrombophilia/Thrombosis Investigations: <u>https://www.albertahealthservices.ca/frm-21911.pdf</u>
- Special Coagulation Testing Requisition Hemostasis Investigations: <u>https://www.albertahealthservices.ca/frm-21905.pdf</u>
- Community Providers/Prescribers requesting Antiphospholipid Syndrome Investigations may continue to use the general laboratory requisition, or may also use the Special Coagulation Testing Requisition for Thrombophilia/Thrombosis Investigations if additional related testing is indicated.

Action Required

- Providers/Prescribers must use the appropriate ordering workflows for Hemostasis and Hereditary Thrombophilia/Thrombosis Investigations, Antiphospholipid Syndrome Investigation and Special Coagulation, as described above.
- Providers/Prescribers must update any existing Personalized Preference Lists, Order Sets and Therapy Plans that or Thrombophilia include orders for specialty Hemostasis testing.

Effective Immediately

Questions/Concerns

• Etienne Mahe, Hematopathologist & Medical Informatics Lead, South Sector <u>Etienne.mahe@albertaprecisionlabs.ca</u>; 403-944-5290

Approved by

- Art Szkotak, Hematology Clinical Section Chief, APL North Sector artur.szkotak@albertaprecisionlabs.ca; 780-407-7104
- Carolyn O'Hara, Chief Medical Laboratory Officer, Alberta Precision Laboratories <u>Carolyn.OHara@albertaprecisionlabs.ca</u>